Previous Article | Next Article ![]()
Journal of Virology, August 2001, p. 7602-7611, Vol. 75, No. 16
Division of Human Gene Therapy, Departments
of Medicine, Pathology, and Surgery, Gene Therapy
Center,1 Division of Gynecologic
Oncology, Department of Obstetrics and
Gynecology,2 and Department of
Biochemistry and Molecular Genetics,3 University
of Alabama at Birmingham, Birmingham, Alabama 35294
Received 5 March 2001/Accepted 4 May 2001
Replication-competent adenoviruses are being investigated as
potential anticancer agents. Exclusive virus replication in cancer cells has been proposed as a safety trait to be considered in the
design of oncolytic adenoviruses. From this perspective, we have
investigated several adenovirus mutants for their potential to
conditionally replicate and promote the killing of cells expressing human papillomavirus (HPV) E6 and E7 oncoproteins, which are present in
a high percentage of anogenital cancers. For this purpose, we have
employed an organotypic model of human stratified squamous epithelium
derived from primary keratinocytes that have been engineered to express
HPV-18 oncoproteins stably. We show that, whereas wild-type adenovirus
promotes a widespread cytopathic effect in all infected cells, E1A- and
E1A/E1B-deleted adenoviruses cause no deleterious effect regardless of
the coexpression of HPV18 E6E7. An adenovirus deleted in the CR2 domain
of E1A, necessary for binding to the pRB family of pocket proteins,
shows no selectivity of replication as it efficiently kills all normal
and E6E7-expressing keratinocytes. Finally, an adenovirus mutant
deleted in the CR1 and CR2 domains of E1A exhibits preferential
replication and cell killing in HPV E6E7-expressing cultures. We
conclude that the organotypic keratinocyte culture represents a
distinct model to evaluate adenovirus selectivity and that, based on
this model, further modifications of the adenovirus genome are required
to restrict adenovirus replication to tumor cells.
Among human cancers, one of the most
distinctive features of anogenital carcinomas is its virological
nature. Numerous reports have established the causal association of
human papillomavirus (HPV) infections with squamous carcinomas and
adenocarcinomas of the anogenital tract (9, 49). Over 95%
of cervical tumors contain integrated HPV sequences that belong to the
oncogenic HPV group (HPV16, -18, and related types) (49)
and consistently express papillomavirus early 6 and 7 oncogenes
(38, 42). E6 and E7 oncoproteins interact with the master
cell cycle regulatory proteins, p53 and pRB, respectively (17,
36), and are able to immortalize primary keratinocytes in vitro
and cause cell transformation in cooperation with other oncoproteins,
such as activated Ras (34, 37, 44). Furthermore,
continuous expression of E6 and E7 oncoproteins is necessary for the
maintenance of the transformed phenotype. These properties have made E6
and E7 targets of various experimental therapeutics, including
vaccination-, antisense RNA-, and ribozyme-based approaches (4,
11, 41).
Although a virus-based therapeutic approach for the treatment of cancer
is not a novel concept, recent years have witnessed with increasing
attention the design of new oncolytic adenoviruses (for a review, see
reference 1). Since the discovery of adenovirus in 1953, the knowledge about adenovirus biology and the interaction with its
hosts has helped identify the need to introduce safety traits, such as
the restriction of adenovirus replication to tumor cells. In this
regard, two major approaches have been developed to achieve
tumor-specific replication, namely, controlling adenovirus early gene
expression by a tumor-specific antigen promoter (2, 35,
53) and introducing viral genomic deletions that affect viral
protein functions dispensable in cancer cells (8, 18). Despite the conceptual validity of these approaches, demonstrating replication selectivity has proven to be difficult due, in part, to the
incomplete knowledge of all viral protein functions and to the lack of
appropriate models to study adenovirus replication in a physiological setting.
Based on functional similarities described for certain HPV and
adenovirus proteins, we believe that a window of opportunity exists in
the design of replication-selective adenovirus for HPV-associated neoplasias. In particular, both oncogenic papillomaviruses and adenoviruses have evolved similar mechanisms to usurp the cell cycle
regulation in order to facilitate viral DNA replication (15,
39). They do so by targeting the same cell cycle regulators, pRB
and related pocket proteins, p107 and p130, through the adenovirus E1A
and HPV E7 proteins (12). E1A is the first transcription unit to be expressed upon adenovirus infection of cells in culture and
is required for cell cycle mobilization and transactivation of other
virus early promoters. The E1A polypeptides encoded by the 12S and 13S
mRNAs share sequence homology with the HPV E7 protein in the conserved
regions (CR) 1 and 2, the same domains that bind and inactivate pRB and
related pocket proteins (16). Most importantly, E1A 12S
and HPV E7 can transactivate the adenovirus E2 promoter in reporter
assays in vitro (7, 32, 33), as well as cellular genes
involved in S-phase entry (48), whose promoters contain
E2F binding sites. This is mediated by the release of the pRB-histone
deacetylase complexes from transcription factor E2F recruited to the
promoters (10). However, neither HPV E7 nor E1A 12S can
transactivate adenovirus E3 and E4 promoters (32), for
which the CR3 domain present only in the E1A 13S product is required.
Efficient promoter activation by the 13S product requires cooperation
between the CR1 and CR3 domains, since E1A mutants containing large CR1
deletions, affecting binding to both pRB and p300, activate viral early
promoters poorly (50). In this context, the HPV16 E7
protein has been shown to restore the transcriptional activity of CR1
deletion adenovirus mutants (51). Therefore, it is
conceivable that certain replication-defective adenovirus mutants may
be complemented by HPV oncogenes, thus restricting their replication to
HPV-positive cancer cells.
In the present report, we have studied the replication of several E1
mutants in organotypic cultures of primary human keratinocytes (hereafter referred to as raft cultures). In the absence of a relevant
animal model to study human adenovirus replication, we chose to perform
this study in the raft system rather than in submerged cultures,
because (i) commonly employed submerged cultures may have different
properties from epithelial tissues in vivo (30), (ii) the
ability of adenovirus to replicate varies upon the epithelial tissue
origin and differentiation stage (5), (iii) the raft
culture is a close representation of the tissue architecture found in
the cervix (14), and (iv) we can take advantage of the
squamous differentiation-dependent HPV biology to investigate
adenovirus replication in cells that do or do not express E6E7 genes
simultaneously in one tissue.
To recapitulate the differentiation-dependent expression of HPV18 E6E7
oncogenes in this model, we have employed a recombinant retrovirus
carrying an HPV18 E6E7 expression cassette under the control of the
native HPV18 enhancer and E6 promoter located in the upstream
regulatory region (URR) (13). Under physiological conditions, this promoter is repressed in the basal and parabasal strata of a fully stratified epithelium but is upregulated upon squamous differentiation into spinous and granular cells
(30). Thus, E6E7 expression occurs in differentiated cells
as opposed to basal cells such that E7 reestablishes S phase in a
subset of postmitotic keratinocytes (13). By using this
model, replication of various adenoviruses can be examined in normal
proliferating basal or parabasal cells, in postmitotic,
differentiated cells, and in differentiated cells expressing HPV18 E6
and E7. Here we describe the pattern of replication of several
adenovirus E1 mutants in the raft culture system.
Adenoviruses.
With the exception of Ad Recombinant retroviruses and raft cultures.
Organotypic raft
cultures of neonatal foreskin keratinocytes were essentially prepared
as described elsewhere (30). Recombinant Moloney murine
leukemia retroviruses were used to transduce HPV18 E7 or E6E7 into the
raft cultures and have been described elsewhere (13).
These vectors expressed the neomycin resistance gene from the simian
virus 40 promoter, and the HPV genes from the native HPV URR.
Retroviruses were generated in the Am12 amphotrophic packaging cell
line, and culture supernatant was used to infect keratinocytes for
4 h. The next day, selection of transduced cells with 250 µg of
G418 (Life Technologies, Inc., Rockville, Md.) per ml was conducted for
2 days. The antibiotic was removed, and the cells were allowed to
recover for another 2 to 4 days. Prior to being transferred onto dermal
equivalents, keratinocytes were infected with adenovirus as follows. To
calculate the adenovirus dose accurately, the keratinocytes transduced
by HPV-containing retroviruses or normal keratinocytes were plated at
the same density in multiple wells. On the day of infection, one well
was trypsinized and the cell number was determined. The other wells
were each exposed for 4 h to adenoviruses at a multiplicity of
infection (MOI) of 1 PFU/cell in serum-free keratinocyte medium. Upon
transfer onto dermal equivalents, a small cell suspension aliquot was
placed in an eight-well chamber slide for adenovirus E1A immunostaining (Adwt300, Ad Immunoprecipitation and Western blot.
SiHa cells grown in
10-cm culture dishes were infected with Adwt300 or CB016 at an MOI of
20. At 15 h after infection, cells were scraped off the plates,
and cell pellets were lysed in 50 mM Tris (pH 8.0), 5 mM EDTA, 0.1%
Triton X-100, and 250 mM NaCl for 30 min on ice. Lysates were cleared
by centrifugation and then immunoprecipitated with 0.5 µg of anti-E1A
mouse monoclonal antibody M73 (Oncogene Research, Boston, Mass.), plus
20 µl of protein A/G-agarose (Santa Cruz Biotech, Santa Cruz, Calif.)
for 3 h at 4°C. Immunoprecipitates were washed three times in
cold lysis buffer and resuspended in electrophoresis sample buffer. Sample aliquots were electrophoresed in 7.5 or 12% acrylamide gels,
transferred to polyvinylidene difluoride membranes, and immunoblotted
with either anti-E1A M73 monoclonal antibody (Oncogene Research), mouse
anti-Rb monoclonal antibody, rabbit anti-p107 polyclonal antibody, or
rabbit anti-p300 polyclonal antibody (Santa Cruz Biotech) in
Tris-buffered saline (TBS; 20 mM Tris [pH 7.6], 137 mM NaCl)
containing 0.2% Tween 20 at a concentration of 1 µg/ml for 1 h
at room temperature (RT). Membranes were washed three times in
TBS-0.1% Tween 20 and incubated with the appropriate peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin antibodies (Amersham Pharmacia, Piscataway, N.J.) at a 1:200 dilution in TBS-0.2% Tween 20 for 1 h at RT. Membranes were washed and developed by enhanced chemiluminescence (Amersham).
Immunofluorescence.
For antigen retrieval, sections were
deparaffinized, rehydrated, and treated with 10 mM citrate buffer (pH
6.0) at 95°C for 10 min. For double detection of BrdU and E1A,
antibody reactivity to E1A was first revealed with the anti-E1A mouse
monoclonal antibody M73 (Oncogene) at a final concentration of 2 µg/ml, followed by Alexa 594-coupled goat anti-mouse secondary
antibody (Molecular Probes, Eugene, Oreg.) at a 1:200 dilution. A final
incubation was performed with fluorescein isothiocyanate (FITC)-labeled
anti-BrdU monoclonal antibody (1 µg/ml) (Boehringer Mannheim,
Indianapolis, Ind.). For hexon staining, sections were incubated with
goat polyclonal anti-Ad2 hexon antibody (Chemicon, Temecula, Calif.) at
a 1:300 dilution, followed by incubation with Alexa 588-conjugated
donkey anti-goat secondary antibody (Molecular Probes) at a 1:200
dilution. All sections were mounted with Gel/Mount (Biomeda). The
photomicrographs in Fig. 3 and 6 were captured with either a Texas red
or FITC filter in an Olympus IX70 inverted fluorescence microscope.
Individual images were merged by means of the Adobe Photoshop 5.5 application program.
Quantification of adenovirus genome copies.
Raft cultures
were infected with adenovirus at an MOI of 0.1 and processed on day 8 of culture. Raft cultures were washed once with PBS and separated from
the dermal equivalent by gently peeling off the epithelium. Total
genomic DNA was purified from these cultures by using the DNeasy Qiagen
kit, and recovered in a volume of 200 µl. Real-time PCR (LightCycler;
Roche) was performed with oligonucleotides to the E4 region. The
sequences of the primers used were as follows: forward E4 primer,
5'-TGACACGCATACTCGGAGCTA-3'; reverse E4 primer,
5'-TTTGAGCAGCACCTTGCATT-3'; and probe,
5'-AAGCTTGTTGCATGGGCGGCG-3'. For quantification, a standard
curve with a known number of viral DNA copies from 0 to 108
spiked into genomic DNA from a mock-infected raft culture was used. In
parallel, the amount of genomic DNA per raft was quantified based on
the determination of actin gene copies. The primers sequences were as
follows: forward actin primer, 5'-CAGCAGATGTGGATCAGCAAG-3'; reverse actin primer, 5'-CTAGAAGCATTTGCGGTGGAC-3'; and
probe, 5'-AGGAGTATGACGAGTCCGGCCCCTC-3'. A standard curve was
performed with known amounts of human genomic DNA (Clontech) from 200 to 0 ng.
Figure 1A depicts the E1A region of
the adenoviruses used in this study. With the exception of Ad
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.16.7602-7611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Papillomavirus E6E7-Mediated Adenovirus Cell
Killing: Selectivity of Mutant Adenovirus Replication in Organotypic
Cultures of Human Keratinocytes
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
24
(18), which was grown in A549 cells, Adwt300
(25), Addl312 (40), and Ad
gal
(3) were grown in 293 cells and purified by CsCl gradient
centrifugation as previously described (19). To minimize
the expansion of E1A-positive recombinants that could generate from
growth in 293 cells, Addl312, Ad
gal, and CB016 viruses
were never propagated over four passages. CB016 virus was generated as
follows. A derivative of plasmid pXC1 (containing the left 5,766 bp of
adenovirus 5 [Ad 5]) (Microbix, Hamilton, Ontario, Canada) was made
by religation after digestion with XbaI and NdeI.
Then, a deletion spanning amino acids 27 to 80 of E1A was introduced by
using an oligonucleotide (5'-CAG CTG ATC GA GAG CTC ACT TTT CCG
CCG-3') flanking the deleted sequence as instructed in the
Transformer site-directed mutagenesis kit (Clontech, Palo Alto,
Calif.). An EcoRI-BspEI fragment was recovered from the deleted plasmid and cloned in the same sites in pXC1-
24 shuttle vector containing a deletion from amino acids 122 to 129 of E1A
(18). The resulting plasmid (pCB016) was cotransfected with pBHG10 (Microbix, Hamilton, Ontario, Canada) in 293 cells. Plaques
were expanded and viral DNA was extracted by a spermine-based method
and sequenced. A plaque showing the correct E1A sequence was further
expanded for CsCl banding. Virus stocks were titered by plaque assay in
293 cells.
24, and CB016) or X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) staining (Ad
gal) 24 h later. These assays revealed that about 90%
of keratinocytes had been infected. Thus, there appeared to be a higher
percentage of E1A-positive cells than expected from MOI of 1 based on
virus titers determined in 293 cells. Raft cultures were allowed to
differentiate for the time indicated in the text, and bromodeoxyuridine
(BrdU) was added to a final concentration of 50 µg/ml for the last 12 h of culture. The cultures were then harvested by a 3-h formalin
fixation and paraffin embedding. Sections (4 µm) were
stained with hematoxylin and eosin (H-E) according to standard
procedures. To detect
-galactosidase activity, cultures were fixed
in 2% formaldehyde-0.2% glutaraldehyde for 1 h and then
incubated with X-Gal (1 mg/ml) in phosphate-buffered saline (PBS)
containing 5 mM potassium ferricyanide-5 mM potassium ferrocyanide-2 mM MgCl2 overnight at 37°C before being
paraffin-embedded.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
gal,
which carries a deletion of the entire E1 region, the remaining
adenoviruses contain total or partial deletions of E1A, while retaining
E1B. Ad
gal harbors a substitution of E1A and E1B with a
-galactosidase expression cassette under the control of the
cytomegalovirus promoter (3). Addl312 has a
complete deletion of E1A from nucleotides 448 through 1349 of Ad5
(40). Ad
24 is deleted of E1A amino acids 122 to 129 within the CR2 domain (18). CB016 harbors two deletions of
amino acids 27 to 80 and 122 to 129, affecting the CR1 and CR2 domains,
respectively. As demonstrated by immunoprecipitation of E1A and
E1A-bound proteins from infected SiHa cells, CB016 expresses a
truncated set of E1A products that are unable to bind p300, pRB, and
p107, in contrast to wild-type E1A (Fig. 1B).

View larger version (34K):
[in a new window]
FIG. 1.
(A) Structure of the E1A regions of the adenovirus used
in this study (for clarity, the E1A 13S-derived polypeptide is shown).
(B) Immunoprecipitation of E1A and E1A-bound cellular proteins. SiHa
cells were mock infected or infected with CB016 or Adwt (20 PFU/cell),
and E1A was immunoprecipitated in nondenaturing conditions. E1A
immunoblotting reveals a truncated set of E1A protein species for CB016
as opposed to Adwt; coprecipitation of pRB, p300, and p107 by CB016 E1A
is abrogated.
To investigate the outcome of raft culture infection with the
adenovirus mutants described above, primary human foreskin
keratinocytes were isolated and transduced with a retroviral vector
expressing HPV18 oncoproteins, as described in Materials and Methods.
Normal (untransduced) primary human keratinocytes and E6E7-transduced keratinocytes were infected with the various adenoviruses at an MOI of
1 PFU/cell. The cells were then transferred onto a dermal equivalent
and allowed to differentiate at the air-medium interface for 10 days.
To monitor E7-mediated reactivation of S phase, cultures were labeled
with BrdU 12 h prior to harvesting by fixation in formalin.
Cultures were paraffin embedded and sectioned for histological and
biochemical analyses. Figure 2 shows the
histology of control raft cultures and cultures infected with
retroviruses, adenoviruses, or both.
|
Wild-type Ad5 induces a widespread cytopathic effect in all infected cultures. Adwt300 infection caused a widespread cytopathic effect in all the cultures with or without HPV18 E6E7 (Fig. 2). The epithelium appeared disorganized, and condensed cell nuclei were abundant. The mere existence of a dead epithelium indicated that replication of Adwt300 did not completely prevent epithelium stratification in the early phases of raft culture development or, alternatively, that Adwt requires epithelium stratification and differentiation to give rise to a productive infection.
Adenovirus mutants harboring entire deletions of E1A or E1A-E1B
have no effect on raft culture development, regardless of HPV E6E7
expression.
Albeit generally considered replication deficient, E1A
and E1A-E1B-deleted adenoviruses have been shown to replicate in
certain conditions, such as in cells with E1A-like functions (26,
40, 43). To test the hypothesis that such functions may be
provided by the HPV18 oncoproteins, we infected normal and
E6E7-transduced raft cultures with these adenovirus mutants (Fig. 2).
Neither Addl312 nor Ad
gal infection induced any
cytopathic effect in the infected raft cultures, regardless of the
expression of E6E7. To substantiate Ad
gal infection, we monitored
the expression of the
-galactosidase transgene by X-Gal staining. In
uninfected raft cultures, no
-galactosidase activity was detected
(not shown), as reported previously (30). In the
Ad
gal-infected culture, it was detected only in the enucleated outer
squames (Fig. 2). We believe that these residual signals correspond to
the expression of
-galactosidase in cells that did not divide
extensively before transiting to the surface and undergoing terminal
differentiation. In contrast, cells that divided many times before
differentiation would have diluted adenovirus genomes and diluted
-galactosidase activity that would be too low to detect. Indeed, we
did not detect Ad
gal genomes by in situ hybridization with
hexon-directed DNA probes in the normal or E6E7 raft cultures (data not
shown). Taken together, these results indicate that at the MOI of 1 PFU/cell used in these experiments, adenoviruses deleted of the entire E1A region cannot be complemented for replication in E6E7-expressing raft cultures.
An adenovirus mutant harboring a deletion of the pRB-binding domain
of E1A exhibits no selectivity of replication.
Since the presence
of the entire E1A provides no selectivity of replication and a complete
deletion of E1A cannot be complemented by HPV18 E6E7 in the raft
cultures, we hypothesized that smaller deletions affecting distinct
functional domains may confer a restricted replication which can be
complemented by E6E7. Ad
24, which has a deletion of amino acids 122 to 129 in E1A CR2, has been proposed as a selective oncolytic agent in
the treatment of gliomas and other cancers (18, 20). We
therefore studied whether this small deletion could confer a more
HPV-specific phenotype in the raft cultures. Upon infection at an MOI
of 1 PFU/cell, H-E staining of the resulting raft culture revealed a
widespread cytopathic effect similar to the one induced by Adwt300 in
normal and in HPV E6E7-expressing cultures (Fig. 2), indicating lack of
replication selectivity.
CB016 preferentially replicates in HPV18 E6E7 expressing
cultures.
The fact that the CR2 deletion in Ad
24 was not
sufficient to confer selective replication prompted us to delete
additional E1A functions that could be complemented by HPV proteins.
Transcomplementation of E1A amino terminal deletions by HPV16 E7 has
been described (51). This deletion affects the CR1 domain,
and therefore the binding to pRB and p300 but not to p107 and p130, a
function that resides in the CR2 domain. Because E7 can also bind to
these pocket proteins, we hypothesized that CR1 and CR2 are both
dispensable for adenovirus replication in the presence of HPV E7.
Consequently, we generated adenovirus mutant CB016 (Fig. 1) and
investigated its behavior in the keratinocyte raft culture.
24, Addl312, and Ad
gal,
CB016 showed distinct patterns of replication in the normal versus the E6E7-transduced raft cultures. In normal cultures, CB016 produced virtually no cytopathic effect in the main central portion of the
cultures (Fig. 2) except some localized effect in the edge of the
cultures (not shown). However, in E6E7-transduced cultures, cytotoxicity was widespread and confined to the differentiated strata
normally comprising spinous and granular cells. These areas appeared
disorganized and contained many enucleated cells. Some remaining nuclei
appeared condensed and pycnotic. The basal and parabasal strata were
spared from this cytopathic effect, in agreement with the spatial
distribution of E6E7 expression (24).
To ascertain that the histopathology observed in CB016-infected raft
cultures was attributed to adenovirus replication and progeny
production, we performed immunofluorescence staining to detect BrdU,
adenovirus E1A protein, and adenovirus late protein hexon (Fig.
3). In mock-infected normal cultures,
incorporation of BrdU was confined exclusively to the basal or
parabasal proliferating cells. In normal CB016-infected cultures, E1A
and hexon expression was scarce, with the exception of the margin of
the cultures in which it was more pronounced (not shown). In uninfected
but E6E7-transduced cultures, incorporation of BrdU was detected in a
subset of both basal and suprabasal cells, as described previously
(24). In CB016-infected, E6E7-transduced raft cultures,
adenovirus E1A and hexon proteins were localized within the suprabasal
lesion previously identified by hematoxylin-eosin staining.
Furthermore, DNA in situ hybridization of the adenovirus genome
confirmed the presence of adenovirus DNA in the remaining nuclei of the
cells within that area, which also stained positive for hexon (not
shown). However, only cells in the basal or parabasal strata
incorporated BrdU. We conclude that the adenovirus had specifically
replicated in and killed the E6E7-expressing differentiated suprabasal
cells prior to exposure to BrdU. Taken together, these results indicate that CB016 replication is complemented in HPV18 E6E7-expressing keratinocytes.
|
|
CB016 replicates in normal raft cultures with a delayed kinetics
relative to HPV18 E6E7-expressing cultures.
Finally, we examined
the temporal replication of CB016 in the raft cultures. For this
purpose, three CB016-infected normal or E6E7-transduced culture
replicas were harvested at days 8, 11, and 14 postinfection. Uninfected
raft cultures were harvested and morphologically evaluated on the same
time points. As shown in Fig. 5A, the
uninfected normal cultures revealed a time-dependent thinning of the
epithelium, along with increased orthokeratosis. We believe this is a
consequence of the gradual decrease of the keratinocyte proliferating
capacity. In contrast, uninfected E6E7-transduced cultures maintained a
constant epithelium thickness, with only slight orthokeratosis. We
suggest that this is due to a delay in terminal differentiation or
programmed cell death brought about by the expression of E6E7
oncoproteins.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Adenovirus-mediated oncolysis is a rapidly growing field with the potential for conceptualization of new agents (1). So far, two distinct strategies have been described to achieve tumor-specific adenovirus replication. The first utilizes transcriptional control of early viral genes with tumor-specific antigen promoters. The second incorporates genomic deletions that affect functions dispensable in cancer cells. We have searched for a new strategy to restrict adenovirus replication to HPV-positive cells, on the basis of the functional complementation of replication-defective Ad mutants by HPV oncoproteins. Based on the cellular proteins that they bind to, as well as the mechanisms involved in mobilizing the cell cycle or preventing cellular apoptosis, functional homologues for E6 and E7 have been identified in the adenovirus as products of the E1B and E1A transcriptional units, respectively. We have taken advantage of these similarities to study the potential of several adenovirus mutants as selective cytolytic agents.
One of the main issues that the field of adenovirus-mediated oncolysis faces is the lack of experimental animal models to study selectivity of replication and toxicity in normal human tissues, especially those surrounding the target tumors. An alternative to this deficiency has been the employment of cultured cell lines and primary cultures. However, these cultures may not display a well-differentiated phenotype and only provide a bidirectional mode of adenovirus spread. For this reason, the use of organotypic cultures of human keratinocytes to investigate the replication selectivity of adenoviruses may provide information on virus-associated toxicity in a three-dimensional setting. This fact, coupled to the multiple differentiated cell phenotypes found in a stratified squamous epithelium, which can closely regulate adenovirus replication, makes the raft cultures system unique in the assessment of adenovirus mode of replication and propagation.
The HPV URR shows a differentiation-dependent pattern of activation (47). Interestingly, the cytolytic pattern generated by Adwt infection, with the appearance of a pseudostratified epithelium, indicates that adenovirus replication also depends on tissue differentiation. Earlier reports have suggested that adenovirus replication depends on keratinocyte differentiation (6, 47). One possible explanation is that the activation of viral early promoters, such as E1, may be dependent on keratinocyte differentiation, as is the case for papillomaviruses. In this regard, the E1 regulatory region has been reported to contain enhancers that are differentiation dependent (21). In addition, preliminary results indeed suggest that the E1A promoter becomes transcriptionally active upon keratinocyte differentiation in upper spinous cells (F. Noya et al., unpublished results).
The deletion of the CR2 domain found in Ad
24 (or mutant
dl922) has been found to confer selectivity on the basis of
its reduced replication in growth-arrested versus proliferating primary
epithelial cells and cancer cell lines (18, 20). In our
model, this mutant exhibits a behavior similar to the Adwt and is
cytotoxic to normal raft cultures even at a low MOI. This observation
suggests that, in this system, the inability to bind pRB and related
pocket proteins can be somehow compensated for by other adenoviral
proteins. In this regard, an adenovirus mutant containing a similar CR2
deletion has been shown to initiate cellular DNA synthesis, by
mechanisms presumably involving binding to p300, a function that is
preserved in Ad
24 (22). More recently, the E4 open
reading frame 6 or 7 protein has been shown to bind pRB and induce
virus DNA replication and cell cycling (29). Therefore,
adenovirus has alternative pathways to facilitate viral and cellular
DNA replication in normal raft cultures. The discrepancy with the
previous published reports may be due to the distinct culture systems
and certain characteristics that can only be revealed in organotypic cultures.
In contrast, we have not detected replication of adenovirus mutant
dl312 or Ad
gal in this model in the absence or in the presence of E6E7. Although several studies have shown that E1A deletion
mutants can be transcriptionally activated by cellular proteins with
E1A-like functions (26, 43) and that HPV E6 and E7 share
functional similarities to adenovirus E1B and E1A, our study shows that
these adenoviral functions cannot be provided by cellular proteins or
by HPV oncoproteins in the raft culture system. Preliminary experiments
performed at an MOI of 10 PFU/cell have confirmed this observation
(data not shown). However, infection at a 100 MOI caused a
deterioration of both normal and HPV E6E7-expressing epithelia. We
believe this is due to uncontrolled early adenovirus gene expression
and replication, which can occur at high MOI (27, 40, 52).
Therefore, among the E1A mutants studied, only a CR1-CR2 double-deleted E1A adenovirus mutant can preferentially replicate in and kill HPV18 E6E7-expressing keratinocytes. The pattern of viral DNA replication, late protein expression, and virus-associated cell toxicity correlates with HPV E6E7 expression. Of note is the time-dependent onset of cytopathicity associated with CB016 infection. Ballooning degeneration observed in day 8 E6E7-expressing cultures represents an early cytopathic effect that occurs after complete epithelium stratification and differentiation. The absence of this phenotype in the day 8 normal cultures indicates complementation of CB016 by HPV18 E6E7. Interestingly, this kind of virus-induced histopathology has also been reported in keratinocyte raft cultures as a result of herpes virus type 1 infection (46). In contrast, later time points revealed a morphologically abnormal, E6E7-transduced epithelium in which adenovirus hexon protein, and presumably whole adenovirions, are abundant. We believe this may be the result of massive adenovirus replication and lateral spread, which in turn causes cell death along with acute morphological changes.
A recent report has established that the expression of the coxsackie-adenovirus receptor (CAR) correlates with the undifferentiated state of oropharyngeal keratinocytes, being detected in the basal strata but undetectable in the suprabasal layers (23). This suggests that adenovirus would require the infection of basal cells, which are normally unexposed and inaccessible, in order to give rise to a productive infection in a stratified squamous epithelium. In the present study, adenovirus infection was performed in submerged keratinocyte cultures, a mostly undifferentiated cell population, prior to stratification and differentiation. We speculate that after the infection of basal undifferentiated cells, the adenovirus genome is carried over across the culture as cells stratify. Upon cell differentiation, the adenovirus E1A gene is transactivated by specific cellular factors and adenovirus replication takes place. In the case of Adwt, replication is unrestricted in normal cultures, resulting in profound epithelial disorganization and widespread tissue disintegration. As for CB016, despite E1A transactivation in differentiated cells, the particular deletions introduced in this gene significantly reduce the efficiency of replication in normal raft cultures. In contrast, in E6E7-transduced cultures, cell differentiation also results in activation of E6E7 transcription, a condition promoting efficient CB016 replication. Because of the reported absence of CAR in the differentiated strata, we speculate that other receptors may contribute to the lateral spread of the virus in the upper layers. Nevertheless, the distribution of CAR in our model, especially in cells expressing E6E7 oncoproteins, warrants further investigation.
Our results show that, despite the preferential replication of CB016 in E6E7 expressing keratinocytes, replication is not completely abrogated in normal cultures. Rather, this virus has a slow replication kinetics and low virus yield that culminates in evident cytopathicity on day-14 normal cultures. The finding that the margin of the cultures frequently display virus-induced cytopathicity may reflect that, relative to cells away from the growing margin, these cells have distinct growth properties that affect virus replication.
Collectively, our observations suggest that careful modifications of the adenovirus genome are warranted to further restrict replication to HPV E6E7 cells. In this regard, other genomic deletions affecting E4 ORF6 and ORF7, whose protein has recently been shown to interact with pRB (29), could be combined with the CB016 deletions. Additionally, controlling transcription of viral genes with exogenous promoters may add a different level of selectivity. It is possible, however, that extensive modifications of viral transcription and/or viral protein functions could alter the oncolytic ability or potency of the resulting virus. Therefore, a compromise between safety (selectivity) and efficacy (potency) will be necessary to achieve the highest therapeutic index. Another line of improvement that could be superimposed on CB016 is at the level of receptor binding, either to restrict infection to tumor cells or to broaden its tropism and avoid the resistance of tumors that have lost CAR expression (45).
In summary, complementation of adenovirus replication by viral oncoproteins responsible for HPV-induced carcinogenesis in combination with the study of adenovirus replication in a human organotypic model are novel additions to the field of conditionally replicative adenoviruses with broad therapeutic implications. An imminent therapeutic application for an adenovirus mutant, such as CB016, would be as an oncolytic agent in HPV-associated cancer. Given the role of HPV E6 and E7 proteins in the productive phase of HPV infections, the range of therapeutic applications may be extended to include HPV-associated premalignant lesions (i.e., dysplasias) and benign lesions induced by oncogenic and nononcogenic HPV types. Further studies on the complementation for other adenovirus mutants or by oncoproteins of other HPV types are warranted.
| |
ACKNOWLEDGMENTS |
|---|
We thank Brenda Gossage for excellent technical assistance in the large-scale preparation of the adenoviruses used in this study and Ge Jin for paraffin-embedding and sectioning of the raft cultures. We are also grateful to Gene Siegal for histological examination of the sections.
This work was supported by the U.S. Department of Defense (PC 970193 and PC 991018), NIH grant CA83821, grant CA86881-01, the CapCure Foundation, NIH grant CA36200, and grant DE/CA11910. We thank Thomas Broker for use of the Digital Imaging Microscopy Facility, which was established with funds provided in large measure by the UAB Health Services Foundation and by grant DE/CA11910.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Gene Therapy Center, 1824 6th Ave. South, WTI 620, Birmingham, AL 35294-3300. Phone: (205) 975-0171. Fax: (205) 975-7949. E-mail: cristina.balague{at}ccc.uab.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Alemany, R., C. Balagué, and D. T. Curiel. 2000. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18:723-727[CrossRef][Medline]. |
| 2. | Alemany, R., S. Lai, Y. C. Lou, H. Y. Jan, X. Fang, and W. W. Zhang. 1999. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6:21-25[CrossRef][Medline]. |
| 3. | Alemany, R., S. Ruan, M. Kataoka, P. E. Koch, T. Mukhopadhyay, R. J. Cristiano, J. A. Roth, and W. W. Zhang. 1996. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. 3:296-301[Medline]. |
| 4. |
Alvarez-Salas, L. M.,
A. E. Cullinan,
A. Siwkowski,
A. Hampel, and J. A. DiPaolo.
1998.
Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.
Proc. Natl. Acad. Sci. USA
95:1189-1194 |
| 5. | Aneskievich, B. J., and L. B. Taichman. 1988. Epithelium-specific response of cultured keratinocytes to infection with adenovirus type 2. J. Investig. Dermatol. 91:309-314[CrossRef][Medline]. |
| 6. |
Aneskievich, B. J., and L. B. Taichman.
1988.
Evidence for two points of restriction in the expression of adenovirus type 2 in cultured epidermal keratinocytes.
J. Virol.
62:4365-4368 |
| 7. | Bagchi, S., P. Raychaudhuri, and J. R. Nevins. 1990. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 62:659-669[CrossRef][Medline]. |
| 8. |
Bischoff, J. R.,
D. H. Kirn,
A. Williams,
C. Heise,
S. Horn,
M. Muna,
L. Ng,
J. A. Nye,
A. Sampson-Johannes,
A. Fattaey, and F. McCormick.
1996.
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
Science
274:373-376 |
| 9. |
Bosch, F. X.,
M. M. Manos,
N. Muñoz,
M. Sherman,
A. M. Jansen,
J. Peto,
M. H. Schiffman,
V. Moreno,
R. Kurman, and K. V. Shah.
1995.
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group.
J. Natl. Cancer Inst.
87:796-802 |
| 10. | Brehm, A., E. A. Miska, D. J. McCance, J. L. Reid, A. J. Bannister, and T. Kouzarides. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601[CrossRef][Medline]. |
| 11. | Breitburd, F., and P. Coursaget. 1999. Human papillomavirus vaccines. Semin. Cancer Biol. 9:431-444[CrossRef][Medline]. |
| 12. |
Chellappan, S.,
V. B. Kraus,
B. Kroger,
K. Münger,
P. M. Howley,
W. C. Phelps, and J. R. Nevins.
1992.
Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.
Proc. Natl. Acad. Sci. USA.
89:4549-4553 |
| 13. |
Cheng, S.,
D. C. Schmidt-Grimminger,
T. Murant,
T. R. Broker, and L. T. Chow.
1995.
Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes.
Genes Dev.
9:2335-2349 |
| 14. | Chow, L. T., and T. R. Broker. 1997. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin. Dermatol. 15:217-227[CrossRef][Medline]. |
| 15. | Chow, L. T., and T. R. Broker. 1996. Small DNA tumor viruses, p. 267-301. In N. Nathanson (ed.), Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 16. |
Dyson, N.,
P. Guida,
K. Münger, and E. Harlow.
1992.
Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins.
J. Virol.
66:6893-6902 |
| 17. |
Dyson, N.,
P. M. Howley,
K. Münger, and E. Harlow.
1989.
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
Science
243:934-937 |
| 18. | Fueyo, J., C. Gomez-Manzano, R. Alemany, P. S. Lee, T. J. McDonnell, P. Mitlianga, Y. X. Shi, V. A. Levin, W. K. Yung, and A. P. Kyritsis. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12[CrossRef][Medline]. |
| 19. | Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors, p. 109-128. In E. J. Murray (ed.), Methods in molecular biology, vol. 7. The Humana Press, Clifton, N.J. |
| 20. | Heise, C., T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, and D. Kirn. 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:1134-1139[CrossRef][Medline]. |
| 21. |
Herbst, R. S.,
M. Pelletier,
E. M. Boczko, and L. E. Babiss.
1990.
The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function.
J. Virol.
64:161-172 |
| 22. | Howe, J. A., and S. T. Bayley. 1992. Effects of Ad5 E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology 186:15-24[CrossRef][Medline]. |
| 23. | Hutchin, M. E., R. J. Pickles, and W. G. Yarbrough. 2000. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum. Gene Ther. 11:2365-2375[CrossRef][Medline]. |
| 24. |
Jian, Y.,
B. A. Van Tine,
W. M. Chien,
G. M. Shaw,
T. R. Broker, and L. T. Chow.
1999.
Concordant induction of cyclin E and p21cip1 in differentiated keratinocytes by the human papillomavirus E7 protein inhibits cellular and viral DNA synthesis.
Cell Growth Differ.
10:101-111 |
| 25. | Jones, N., and T. Shenk. 1978. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 13:181-188[CrossRef][Medline]. |
| 26. | La Thangue, N. B., and P. W. Rigby. 1987. An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 49:507-513[CrossRef][Medline]. |
| 27. | Lieber, A., C. Y. He, I. Kirillova, and M. A. Kay. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70:8944-8960[Abstract]. |
| 28. |
Noya, F.,
W.-M. Chien,
T. R. Broker, and L. T. Chow.
2001.
p21cip1 degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7.
J. Virol.
75:6121-6134 |
| 29. |
O'Connor, R. J., and P. Hearing.
2000.
The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection.
J. Virol.
74:5819-5824 |
| 30. | Parker, J. N., W. Zhao, K. J. Askins, T. R. Broker, and L. T. Chow. 1997. Mutational analyses of differentiation-dependent human papillomavirus type 18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differ. 8:751-762[Abstract]. |
| 31. | Patel, D., S. M. Huang, L. A. Baglia, and D. J. McCance. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:5061-5072[CrossRef][Medline]. |
| 32. |
Phelps, W. C.,
S. Bagchi,
J. A. Barnes,
P. Raychaudhuri,
V. Kraus,
K. Munger,
P. M. Howley, and J. R. Nevins.
1991.
Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism.
J. Virol.
65:6922-6930 |
| 33. | Phelps, W. C., C. L. Yee, K. Münger, and P. M. Howley. 1988. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53:539-547[CrossRef][Medline]. |
| 34. |
Pirisi, L.,
S. Yasumoto,
M. Feller,
J. Doniger, and J. A. Dipaolo.
1987.
Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA.
J. Virol.
61:1061-1066 |
| 35. |
Rodriguez, R.,
E. R. Schuur,
H. Y. Lim,
G. A. Henderson,
J. W. Simons, and D. R. Henderson.
1997.
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Cancer Res.
57:2559-2563 |
| 36. | Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136[CrossRef][Medline]. |
| 37. | Schlegel, R., W. C. Phelps, Y. L. Zhang, and M. Barbosa. 1988. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 7:3181-3187[Medline]. |
| 38. | Schwarz, E., U. K. Freese, L. Gissmann, W. Mayer, B. Roggenbuck, A. Stremlau, and H. zur Hausen. 1985. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114[CrossRef][Medline]. |
| 39. | Shenk, T. 1996. Adenoviridae: the viruses and their replication, p. 2111-2148. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, vol. 2. Lippincott-Raven, Philadelphia, Pa. |
| 40. | Shenk, T., N. Jones, W. Colby, and D. Fowlkes. 1979. Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp. Quant. Biol. 44:367-375. |
| 41. | Shillitoe, E. J., P. Kamath, and Z. Chen. 1994. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther. 1:193-204[Medline]. |
| 42. |
Smotkin, D., and F. O. Wettstein.
1986.
Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein.
Proc. Natl. Acad. Sci. USA
83:4680-4684 |
| 43. |
Spergel, J. M., and S. Chen-Kiang.
1991.
Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation.
Proc. Natl. Acad. Sci. USA
88:6472-6476 |
| 44. | Storey, A., D. Pim, A. Murray, K. Osborn, L. Banks, and L. Crawford. 1988. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 7:1815-1820[Medline]. |
| 45. |
Suzuki, K.,
J. Fueyo,
V. Krasnykh,
P. N. Reynolds,
D. T. Curiel, and R. Alemany.
2001.
A conditionally replicative adenovirus with enhances infectivity shows improved oncolytic potency.
Clin. Cancer Res.
7:120-126 |
| 46. | Syrjanen, S., H. Mikola, M. Nykanen, and V. Hukkanen. 1996. In vitro establishment of lytic and nonproductive infection by herpes simplex virus type 1 in three-dimensional keratinocyte culture. J. Virol. 70:6524-6528[Abstract]. |
| 47. | Taichman, L. B., S. S. Reilly, and R. F. LaPorta. 1983. The role of keratinocyte differentiation in the expression of epitheliotropic viruses. J. Investig. Dermatol. 81:137S-140S[CrossRef][Medline]. |
| 48. |
Takahashi, Y.,
J. B. Rayman, and B. D. Dynlacht.
2000.
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression.
Genes Dev.
14:804-816 |
| 49. | Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19[CrossRef][Medline]. |
| 50. |
Wong, H. K., and E. B. Ziff.
1994.
Complementary functions of E1A conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.
J. Virol.
68:4910-4920 |
| 51. | Wong, H. K., and E. B. Ziff. 1996. The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino-terminus-dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct-1 DNA binding activity. J. Virol. 70:332-340[Abstract]. |
| 52. | Yang, Y., F. A. Nunes, K. Berencsi, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369[CrossRef][Medline]. |
| 53. |
Yu, D. C.,
G. T. Sakamoto, and D. R. Henderson.
1999.
Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Cancer Res.
59:1498-1504 |
| 54. |
Zimmermann, H.,
R. Degenkolbe,
H. U. Bernard, and M. J. O'Connor.
1999.
The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
J. Virol.
73:6209-6219 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||